NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.